These connections have fueled interest in whether intentional weight loss can improve outcomes
XLu: Conceptualization, Funding acquisition, Supervision, Writingreview and editing
Recent studies have suggested that novel weight-loss drugs targeting glucagon-like peptide-1 (GLP-1) may also improve HFpEF symptoms, but their effect on important outcomes like hospitalization and death has not been evaluated in large populations
Inform your provider about the complete clinical picture , including the timing of symptom onset relative to Zepbound initiation or dose changes, severity and pattern of breathing difficulties, and any accompanying symptoms such as gastrointestinal distress, palpitations, or lightheadedness
Retatrutide belongs to the glucagon-like peptide-1 (GLP-1) drug class, like the widely used Wegovy and Mounjaro, but its mechanism of action differs